anna: it has been a turbulent year for big pharma.tocks outperformed markets on both sides of the atlantic. let's look at how health care will fare in 2016. good morning. of just how much of performance we saw on both sides of the atlantic. >> this is all in u.s. dollars. y, we got a couple of percentage points for each of forcesopean and u.s., the bigger and broader embassies, such as the stoxx 600 for europe and the s&p for the u.s.. that has been driven, it has not been uniform across the sectors. downd companies in europe 6.6%. down 5.6%., we have had companies that have not done so well share price- wise, but they have been outweighed by the big games. -- the big gains. anna: we have a big range from the negative to that kind of increase. which is stocks are you excited about? >> the way i look at that is to look and see who has the most interesting or potentially volatility inducing news. the top of that chart for europe reports for next year. anna: diabetes, it did really well this year. things we needo to be aware of when we l

to pharma if they're presentation. that can save substantial amount of money for the federal government when it comes to pharmaceutic als and would likely lower to an extent the amount of money that we in the us pay for drugs. at the very least for some medicare patients, i think it could make a big difference for their care. dr. ghosh: that should be done because most of cancer patient is medicare populations. they're not young so we are denying the care to our citizen and it has becoming a care of the privileges. i'm going to give you an example. president obama says that we are providing the healthcare and you can pick and choose. i know a patient who has money to get the platinum product, they get the free care. i know patient who was good and tried to get a product that she can afford, bronze ... she has copay, she doesn't know how to get the care. she cannot pay for it. that we are providing the care to everyone is wrong. we are privileges. actually, the person who can pay the bigger premium, his care or her care

pharma sector did relatively well compared to the s&p, and so did the euro pharma sector..s. beat the europeans. is there anything in that? i don't think so. it is a small amount of companies, so i don't want to read too much into it. on a stock level we had some very interesting moves. eli lilly led the sector in terms of performance, driven by good, clinical data, and everyone knows about diabetes, so that is driving -- anna: you can get sidetracked by the big m&a stories. there are some good clinical stories coming in. what interests you? activee i am an investor. a long-term growth story. all of these companies, everything seems to be a proxy for more growth out right. i'm a bond proxy, in that story continues. that is the story in the making. the market -- we have seen a lot of m&a in 2015. is that going to continue? you mentioned that easy to understand business, why diabetes might be on the rise and this might be an interesting company -- to companies like that stay independent? >> this is a special case because they have a shareholder who is very unlikely to want t

pharma is lagging behind other providers in being paid for value. some companies in a deal with us have been at the table. others have said no, thank you, we don't need to do this. how can we encourage them to be a part of the solution? and i'm wondering, can we -- along those lines, if a company can't explain their price in a way that makes sense, tied to reasonable return to shareholders, why can't we allow importation from europe? >> we're going to stop you there. ken? take that first part of that question. how do we get all the pharmaceutical companies to the table for these value-based and outcomes-based discussions? >> well, i think the reason they should come to the table is the reason why merck did. and thank you for acknowledging that. our shareholders are important to us. patients are important to us. we've existed for 125 years by looking at what's in the best interest of patients. ultimately, we all have to think about the sustainability of this system. if we don't think about the sustainability of the healthcare system there won't be an

>> we have several away from bio tech and pharma. the affordable care act continues to stimulate spending in health care. there are uncompensated care that goes down. we like that. but in addition, you know, some of the more exciting stocks, i continue to like regeneron, which i mentioned before, and for those which would take a bigger risk, there's a company called portola. they have news coming at the turn of the year. they have a prospective approval next year. they're losing money now. there is risk. but we think it's probably a good balance of risk and return. >> just a real quick question regarding the 80% sell-off today. how much is that is really so either a, a one-trick pony or, b, they're not going to be able to get to the finish line or will have to start completely over with this? >> there's worry about getting to the finish line. they are a single lead product. they have other things like that to work on. but they're in severe difficulty right now. >> thank you. >> sam, thank you very much, sir, thank you very much for s

plus the face of evil pharma. martin shkreli, who famously marked up the price of a life-saving drug by over 5,000%. he is arrested for securities fraud. >>> and later, the unwavering strength republican candidates are showing by maintaining lies in the face of the truth. those stories and more just ahead. >>> presidential candidate bernie sanders got a huge endorsement today from the communication workers of america union, representing 700,000 workers nationally. the executive board voted unanimously for sanders after a grassroots poll of its members voted decisively in his favor according to cwa president chris shelton. >> so bernie sanders just won the first election that's happened in this country for president. >> and you and i know that the middle class does well when trade unionism does well. and you and i know how difficult it is for workers across this country to come together and try form a union because they are attacked illegally, unfairly, by employers who are making it so difficult for workers to exe

pharma makes therapies for cancer patients. shire downby 1.7% -- by 1.7%.hey are in takeover talks with axalta.-time -- acceb the chemicals megamerger announced this morning between dow and dupont -- the company's ceo's senate they're not worried about regulators holding up the deal. >> as big as our two companies are, there is to minimize overlap. -- the into the sand same and markets. the actual products do not overlap at all. except the act side. ag side. the minimus overlap. >> the beauty of these companies is wildly broadly play within more the specialty side, they don't go head to head. the synergy potential is there. with very little concern -- thed: he was praising construction of this deal, the novelty of merging them and splitting into three companies. >> that is an ongoing thing. mr. green is a phenomenal architect. he used to be the ceo of tyco where they carried that strategy out. it will be a repetition of that. , thea chemical market chemicals been is that you consolidate within agriculture, agriculture equities and commodity prices have come

plus the face of evil pharma. martin shkreli, who famously marked up the price of a life-saving drug by over 5,000%. he is arrested for securities fraud. >>> and later, the unwavering strength republican candidates are showing by maintaining lies in the face of the truth. those stories and more just ahead. s a developer! its official, i work for ge!! what? wow... yeah! okay... guys, i'll be writing a new language for machines so planes, trains, even hospitals can work better. oh! sorry, i was trying to put it away... got it on the cake. so you're going to work on a train? not on a train...on "trains"! you're not gonna develop stuff anymore? no i am... do you know what ge is? ok, wehere's dad. mom. the twins. aunt alice... you didn't tell me aunt alice was coming. of course. don't forget grandpa. can the test drive be over now? maybe just head back to the dealership? don't you want to meet my family? yep, totally. it's practically yours, but we still need your signature. the volkswagen sign then drive event. zero d

plus the face of evil pharma. martin shkreli, who famously marked up the price of a life-saving drug by over 5,000%. he is arrested for securities fraud. >>> and later, the unwavering strength republican candidates are showing by maintaining lies in the face of the truth. those stories and more just ahead. at&t knows the best kind of holiday... is the kind where everyone gets what they wished for. make this holiday extra happy when you buy one get one free on our most popular smartphones... like the samsung galaxy s6. buy one get one free. so spread some cheer. and capture every minute of it. right now at at&t, buy one get one free on our most popular smartphones. aduring sleep train's ur latriple choice sale.ig for a limited time, you can choose up to 48 months interest-free financing on a huge selection of tempur-pedic models, or choose to save $300 on beautyrest and posturepedic mattress sets. you can even choose $300 in free gifts with sleep train's most popular stearns & foster mattresses. the triple choice s

analysts just published the 2016 outlook for pharma.in your 2016 lookahead, is pharma please and -- poisoned? anwell, i think that is interesting phrase numeral the drug companies. see theyou'll probably rhetoric will continue into 2016. i don't think there is any opportunity that will be lost by politicians if they can. i know another example to use potentially on the price rises and some of- pharma the liquor companies have a putting in. we haveity is that quite a bit of in-depth analysis on this. the probability of changing the law could bring in more control by the government and the drug prices. at least it is low in the near future. i think what is reality is that doing a lot better than they have been in terms of curing patients and meaningfully significantly enhancing the survival of a cancer patient. and pharma companies are pricing in a way they think is relevant. that is where i think payers are more interesting in terms of what they will do. david: this sector has done very well over the last several years compared to the s&

the big boys are piling into isis pharma. stocks have been trading for the last few weeks consolidating recent gains. this is exactly what you want after a big gain. but lang's fees will start going higher. he's calling for an explosive breakout. finally, blueberg. this is the least compelling daily chart of the three. after a recent surge over its 50 hammered, plummeting $8.41, nearly 10% after investors reacted negatively to comments and a general positive piece of research. it suggested there could be a potential delay in one of the lead drug candidates, treatment for a rare blood disorder that allows patients who would otherwise need frequent blood transfusions to get by just fine without them. given that people are told to buy blueberg $204 price target on an $80 stock, lang thinks today's pull-back is a real overreaction. first, the indicator, again, we have got, this is this one, got that bullish crossover we like to see where the black line crossed over the red one. okay? got that. pretty reliable signal. the momentum

if you look at pharma, if for some reason you strike this deal, $500 billion in pharma deals in 2015alone. if you look at hospitals, you see the consolidation there. if you look at drugstore chains, that's happening there. so what the heck is going on with every part of the healthcare system getting bigger and bigger? >> well, i think the pressures on the providers are being driven by changes in the healthcare reimbursement system. that's true i believe both for payers and for the providers. i don't think the pharmaceutical industry as yet is being driven to consolidation because of the consolidation of other parts of the system. i think the consolidation is being more driven by companies that have the cash and want to look for ways for accelerating their portfolio. now, i do think there may be a point, if we continue to see concentration on the other side, and if we do see more government involvement in healthcare than we have today, then that consolidation would be a route the industry would need to take. >> why would it need to take that? >> well, because generally when you do bus

coming up, the rise and fall of the so-called ad boy of pharma.t is next. ♪ the only way to get better is to challenge yourself, and that's what we're doing at xfinity. we are challenging ourselves to improve every aspect of your experience. and this includes our commitment to being on time. every time. that's why if we're ever late for an appointment, we'll credit your account $20. it's our promise to you. we're doing everything we can to give you the best experience possible. because we should fit into your life. not the other way around. david: live from bloomberg's world headquarters in midtown manhattan, you are watching bloomberg television. i am david gura. we have more from our news desk. cosby, theill comedian charged with sexual the firstom 2004, criminal charge in 2004. he was once considered america's favorite the dad, but the comedian has been talked by allegations of sexual assault. those charges were listed today. take a listen. >> the charge we are proceeding on today involves one victim, involves a victim that went to mr. cosby's

pharma. controlling interest in acerta, which is focused on oncology and focusing on a blood cancer blood. they could be doing peak sales of $5 billion. that could be a real steal there. i have to say i like this argument. yesterday's assert to acquisition only likes me like astrazeneca even more. looks like the analysts at morgan stanley have a good reason to change their november. they decided they were about to miss their window and pulled the trigger on december 1st. how about this two-notch downgrade of cummins from buy to sell from bank of america merrill? took place the same day. here's the different story. remember cummins is a big international oriented industrial with a stock that's and a half. 18 months! yet this analyst at bank of america and merrill had a buy rating on the stock since this past january when it was trading at 142. let me see, where'd this one go out? oh, yeah, 85. that's bad. and then nearly 11 months later he downgrades to underperform. the stock but i have to wo

and the bad boy of pharma is fighting back, telling the "wall drugt arnold" that his price hikes led to his arrest. let's head to the markets and we did a bit of a fake out today. almostg out hire, losing all those gains and now we are back to where we started the day. the nasdaq, the biggest gainer, up about .7%. energy stocks have been the biggest laggard all day. let's look at the smp year to date as we get closer to the end of the year. we are lower by a little more than 2% with just eight trading days left. higher inhas finished the past three years, but we are on track to break that will stop this is the seasonality chart and we are on track for our worst december since 2002, when december ended down by more than 6% stop we are on track to be 3%. by a little more than david: not many indications we will be making up that ground by years end ramy:. ramy:especially with some new research coming out saying that a year rally for the s&p is in doubt i'll stop we would need to rally about 2.7% by the end of the year. we've got eight trading days and the s&p has only done that in the

pharma ceo, martin shkreli is home after posting bail. meg terrell joining us with the latest developments from outside his apartment. next. you're watching cnbc first in business worldwide. santa has a magic snow globe for every family. and this year, look at what he put in our driveway. the lexus december to remember sales event is here. lease the 2016 es350 for $349 a month for 36 months and we'll make your first month's payment. see your lexus dealer. i finally did it! ♪ ew, you did it all right. let sparkle paper towels clean it up. do the math - and you'll see sparkle costs less. plus it's perfect for cleaning spills... ...desktops... ...windows... ...and chalkboards. now that's what i call clean. too clean? sparkle. because it's a messy world out there. >> mr. khrkreli posting bail. meg terrell live outside that building. meg where are. >> hi, scott. the latest is that bloomberg and wall street journal are citing sources saying that shkreli is close to stepping down as a ceo of tu aring pharmaceutical. i'm also hearing there is tre

meeb: what folks have told is before a bio pharma startup gets a big break, they have no cash.hey have a promise. they load these guys up with options, and sometimes they make it big. at the top of the list of high-take board you have three bile from a company's. -- bio pharma companies. betty: why is it concentrated? caleb: specifically they are cash-poor and they had these directors that have been with them 10, 20 years, waiting for the big break. they do not have the cash to give them then, so they give them options. in this case, these three are making it big all of a sudden, and their directors are finally being rewarded handsomely. betty: are the shareholders now saying because they are compensated so well they cannot be good stewards for the shareholders? they can't be independent? there are some concerns that this is more than enough to be a person's sole bread and butter. can they come to the company as independent watchdogs for the shareholders over management, when this could easily be the only job they need to make a winning. betty: exactly. they can live off of thi

we have a number of partnerships that we are doing with pharma companies.nd inflammatory bowel disease and parkinson's, we are about to launch a few others. emily: are you going to do human testing yourself here? anne: what we want to do and ,hat we want to do with pharma it will react best if we come to them with a target or a compound with some clinical background. some data about how that is functioning. there is a higher likelihood of success if we can come with that level of information and move that forward. emily: you would do human testing here? anne: we would start doing some of our own clinical research for sure. emily: there is some competition out there. ancestry.com does something similar. they have a partnership with calico. do you see google and calico as competition? anne: no. everything here is based on genetics and in gauging the consumer and making interesting, engaging products on them. calico is focused on anti-aging. i always wish all these companies well. i think it will expand the entire industry. and i want to translate this informa

not exactly the ideal demographic for big pharma. he showed us why some impefrished areas-- impoverished areas are breeding grounds. >>> on the right-hand side is piles of discarded tyres. >> reporter: stray dogs, run-down homes, broken windows, heaven for disease-carrying bugs. >>> on either side you will see these big draining ditches that fill up with water. these provide perfect breeding grounds >> reporter: while they're considered diseases of poverty, they're also perceived as an immigrant problem and that needs to change says the doctor. >>> we've got to get over this mentality that these are not diseases that are coming across our southern border. they're for the most port diseases for transmission here in the united states >> reporter: case in point this woman, born and raised in texas >>> i did not live in a mud hut. i lived here in texas, grew up in a brick matrimonial home. i don't live in poverty. i've never been on a cruise. i've never left and went to another country. >> reporter: yet? <> reporter:

we have done a comparison looking at large pharma versus dietetic. -- versus biotech.looks a little bit like -- there is one big drug, potential patent challenges coming up. people are worried about it. that's why it's getting on a lower multiple than its earnings growth would suggest. so i think 2016, a lot of these companies will have to look at m&a in terms of how they are going to defend their bottom growthnd bring in more for companies like amgen. do these biotechs earned m money? >> a lot of these are in the major profit generating world. what i think is going to be interesting in 2016 is that a lot of the targets for these m&a thes are likely to be in bolts on acquisitions -- full bull ton acquisitions. you, sam fazeli. we are moments away from the european close. caroline hyde has more from london. caroline: really choppy. check this out. a really mixed bag. ftse steaming ahead. germany is lower, italy is lower. i want to focus on the volatility we see in the stock market. stoxx 600 swinging between games and losses. what are volumes like where you are? betty:

backing with non-profits, including the gates foundation, the doctor and the team are doing what big pharma isn't. what happens in here? <> reporter: so far they have made six. they're still in the testing phase, but it's a promise. >>> most of these people have no idea that they're living on the front lines of this. >>> yeah. i mean the level of awareness of the neglected tropical disease is not only among people but also physicians and health care providers. >> reporter: he warns of the effects of these tropical diseases go beyond the physical. it is a huge social cost as well >>> they actually cause poverty and they do that because they make people too sick to go to work. they actually shave iq points off of kids. they reduce intelligence in cognitive abilities among kids >> reporter: no-one, not parents or teachers, are the wiser. most doctors don't screen for neglected tropical diseases. many patients will die. never knowing why. you could say this woman is among the lucky ones >>> if chagas is going to affect my heart, i want to know. i don't want it just to s

we have a number of partnerships that we are doing with pharma companies.upus and inflammatory bowel disease and parkinson's, we are about to launch a few others. emily: are you going to do human testing yourself here? anne: it will be asked best if -- it will react best if we come to them with a target or a compound with some clinical background. some data about how that is functioning. there is a higher likelihood of success if we can come with that level of information and move that forward. emily: you would do human testing here? anne: we would start doing some of our own clinical research for sure. emily: there is ancestry, they do some similar things. they have a partnership with calico. do you see google and calico as competition? anne: everything here is based on genetics and in gauging the consumer and making interesting, engaging products on them. calico is focused on anti-aging. i wish these companies well. i think it will expand the entire industry. i want to translate this information into useful therapeutics. i want to come and say we develope

. >>> up next, another blow for controversial pharma executive.t when we come back. >>> welcome back to "squawk alley." we're watching shares of juniper networks down again today, sharply about 5% or so at this point. the stock's been falling since the open. is currently one of the biggest laggards in the s&p 500. comes after the company has provided information on two possible security issues it discovered that could affect one of its operating systems. telling reuters on friday really the department of homeland security is working with the company as it investigates. the stock is down by about 5% right now, still reeling. three days worth of losses. >> all right, thanks so much. meantime, there's more trouble for controversial and outspoken pharma ceo martin shkreli. kalobios has removed him as ceo, just days after being arrested and charged with misleading investors in his hedge fund. he talked with the "wall street journal," flanked by his lawyers, saying he is being targeted for his highly criticized drug price hike that came earlier this yea

(sherry torkos/pharma cist)"don't use alcohol as a you to fall asleep, but if you have alcohol it can actually cause nighttime awakening."if you can't sleep, torkos says to try to avoid the distracting device we carry around, so don't check cell phone messages or go online to work. this can amp you up.and if you turn on the t-v, watch something that's relaxing or try meditating. 3 triple- a estimates 50 million people will hit the road this holiday season... with another 37 million planning to *fly* to their destination. 3 <> 3 the newest generation of super powers have arrived. over the laser has tripled and the technology just gets better and better. in the quest to look our best lasers are the magic wand to remove scarring,discolorations, and sun damage. they also tighten and re-surface the skin. laser treatments focus a wavelength of high-energy light on the skin. dif

kite pharma. kite is the symbol. over the summer we said there is a good chance it retests at the levels from january and imperative it close above 90. well guess what, we ran up to the $90 level and failed. here is the good news. the stock went from $50 to $90. today's close puts us at a 50% correction of the entire move. yes, the valuations are ridiculous. this is not a company that makes money yet. but the technology works. and it has a 22% short interest. so if you are looking for an entry point, you got it today. >> and are expectations ahead of them. and that is the case. and blue bird traded from where it ipoed around $20 a share to almost $200 a share f. you are a manager and you have losses on your books, this is a name you will sell. shoot first and ask questions later. and so i look at the name and don't think it was the skpepgtations that -- expectations got ahead of them, i think we are in a spooked sector right now. and going into the end of the year, a fund manager will do whatever they could to protec

i like the pharmas. >> seaburg? >> i like the pharma as well. bristol-myers.e the pipeline here and like the stock. bristol-myers is a buyer. >> shout out to stock. >> my kids failed everything today. disney back on the trade again. >> guy adami? >> that was fantastic. >> a play officer. we play, laughs. >> grasso's kids. >> health care, health care. and i'm going to give you pfizer. >> wow. >> which means health care is going to get obliterated tomorrow. >> i'm melissa lee. thanks for watching. see you tomorrow here at 5:00 for more "fast." meantime, "mad money" with jim cramer starts right now. >>> my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere. i promise to help you find it. "mad money" starts now. hey i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends and i'm trying to make you money. my job is to teach and coach you. call me at 1-800-743-cnbc or tweet me @jimcramer. why does the market seem so bad these days? what makes it seem

a tough months to say the least for this small san francisco-based pharma company. it had nothing to do with that drug price increase, nothing to do with the alleged securities fraud, but now, it is in bankruptcy. a lot of collateral damage there. >> indeed. >> all right. >> a lot of damage. thank you, bill. >> see you tomorrow. >>> chris here now with a look >> this isn't saturday or sunday morning. i feel very out of place. i love seeing you guys in the flesh now. >> heavy clouds in his hand right now. and that's what we have outside. another cloudy, gray, dreary day. but that could change a little later on tonight. let's get a look at it the crowds will continue to gather around the tree as we go through the day and evening tonight, but if you're heading out tonight, you want to take the umbrella along to play it safe, not so much an issue during the course of the day. at 43 in the city now. still some chilly numbers north and west of town and again, we are finding temperatures in the mid and upper 30s across northwest sections of new jersey. 36, franklin. a raw,

this hour a closer look at biotech and pharma.meg. >> reporter: 2015 was a rocky year for pharma and biotech. it started off strong but hit a slow down in the second half. here's what to expect for 2016. ipos may slow but m and a is expected to continue. while 2015 saw some massive mergers, 2016 may see drug makers focusing more on building pipelines. analysts expect drug giants to deploy some of their serious cash hoards while incyte is a target. ipos slow their pace. biotech has seen hundreds of new companies entering the public market in the last few years. experts say if this run ends it will be more due to lack of supply than lack of demand. and biotech gets binary. the coming year will bring a number of events that could make-or-break certain biotech stocks. so, a lot has changed after the big bull run we've seen in the last five years. people are saying it's a stock pickers market. >> usually people that manage money and pick stocks, they are the guys that say it's a stock pickers market. most say that. every year, isn't it

she thinks they need patients at the negotiating table along with pharma and pairs. >> let's lock theoor, throw away the key and until somebody comes up with some kind of reasonable answer, nobody leaves the room. >> but first, she needs to find a health plan. bertha coombs, "nightly business report," new york. >>> sally pipes joins us now to talk more about pharmacy benefit managers and the issues affecting pricing of specialty drugs in the u.s. she's the president and ceo of the pacific research institute. welcome, good to have you with us. i want to start at a very basic level to make it real clear. what do pbms do, who pays them and how do they make money. >> pbms are administrators for drug benefit plans. their main clients are insurance plans and those companies that are self-insured. but they also pay out claims to the people that they -- the companies that they cover. they develop formularies which are the types of drugs that are available to people who need to use drugs. and they negotiate discounted prices with drug companies for to try and get lower prices. so they cover ab

that is pharma, biotech, finance and of course some tech as well.ack to you. >> i cannot recall such a fragmented real estate market. i know all real estate is local, but in the scheme of things, very fragmented. >> where it is working, the tightest market you could see and supply is still out there and prices haven't budged. >> and we go an idea from kay reed, with the prices rising more than last month. the home builders trade has worked, up 9% beating the over all market but it hasn't been a straight shot higher. >> not at all. it is steady. and there is still the story out there that they are benefitting from the supply-demand advantage they have in certain segments of the market they are playing but they are not going into the starter homes. >> or luxury. and philip rang the "closing bell" today from sotheby's, a luxury company, they have a dirth in inventory right now. and home builders need to have more faith. >> i think it is the matter of fighting the last war. they don't want to be caught in that again. >> and what happens to mortgage rate

they reached an agreement over its flagship cancer drug with generic drug-maker natco pharma. shares of cellgene rose nearly 10% today to $122.07. >>> norfolk southern spurns another takeover bid from rival canadian pacific. the railroad said regulators will likely reject the merger. canadian pacific says it's disappointed with norfolk's decision and will review strategic alternatives. shares of norfolk southern up just shy of 1% to $86.89. >>> meanwhile, shares of canadian pacific closed up to $128.50. >>> an activist investor carl icahn says he is willing to pay around $1 billion for pep boys. according to a filing, icahn is willing to pay 10 cents more per share than japan's bridgestone. bridgestone has until tomorrow evening to respond. shares of pep boys jumping 3% today to $17.40. >>> the regional cable operator cablevision facing scrutiny from state and city regulators over its deal to sell to french conglomerate altisse. new york state and new york city are concerned the deal would negatively impact consumers. shares of cablevision closing down 0.75% to $31.54. >>> inv

. >> this has been a busy one for biotech and pharma. we wanted to find out what meg's predictions were next a year in the drug industry. >> 2015 was a rocky year for pharma and biotech. it started off strong, continuing a multi-year rally, but hit a slow down in the second half as drug pricing concerns weighed on stocks. here is what to expect for 2016. ibo may slow but m&a is expected to continue. while 2015 saw massive mergers, 2016 may see drug makers focusing more on building pipelines. analysts expect drug giants gilead, johnson & johnson and amgen to deploy some of their serious cash hoards while insight is a topic as a target. while there is political scrutiny analysts say a near term change in policy may be unlikely. biotech has seen hundreds of new companies entering the public market in the last few years and experts say if this run ends it will be more due to lack of supply than lack of demand. >>> and biotech gets binary. analysts say the coming year will bring a number of events that could make or break certain biotech stoc

astrazeneca in advanced talks to buy a company named asserta pharma.ding to the "wall street journal." it doesn't have any drugs on the market but its cancer drug has shown promise in trial. shares were off a fraction to 33.25. >>> it's been a particularly difficult stretch for the trucking industry, in part because they're not shipping as much fracking equipment to shale regions. the sector is also suffering from a shortage of truck drivers. and as morgan brennan reports some companies are finding new recruits to fill those jobs. >> reporter: tiffany dearing doesn't fit the stereotype of a truck driver and she knows it. for the past year as a team driver with her husband she's traveled across the country delivering freight for warner enterprises spending three weeks at a time on the road. when she parks her big rig at a truck stop, people do a double take. >> oh, you drive too? and they kind of step back for a second. they're like oh. oh, really? and i'm like, yeah, i drive. >> reporter: dearing is part of a growing population of women drivers being r

they point out this british big pharma alpha is ready for the development of the department, including new drugs to the point where they have a wave of positive catalysts coming out in 2016. normally i can be skeptical about the cell side research. it opened my eyes to a stock i hadn't liked. they said the expectations had reigned back in. now they pointed out that their bear case is true. they got it right. but after telling you to ignore the stock for a year, now morgan stanley is pounding the table and telling you to buy astrazeneca hand over fist. number 26 is like in another ten days which is why the company believes they can earn 6 -- >> these analysts see some major research and development coming. it should result in three major bloods, there's a novel blood thinner, an asthma treatment and then there's an ovarian cancer drug they're currently testing this cancer franchise. these guys point out astrazeneca is also bringing three huge drugs to market, there's treatment for lung cancer, high potassium levels and chronic obstructive lung disease. they believes they drugs could be

there is a lot of interest in pharma.he banks are getting through their regulatory -- the banking sector could perform better next year. guy: i want to talk to you about that later because the weekend news out of it bif. there is more revelatory work to be done. we will talk about that later. simon weber will stay with us. our radar? limit tell you, bloomberg sources say barclays may cut what percent more of its banking staff. ceo speaks of possibility of cuts coming. 3:16.s the decision comes amid a legal battle. -- a breakup fee -- percent softer. energy stocks have slipped. opec gave up. at a chaotic meeting in vienna, opted to keep pumping in that effort to squeeze nonmember rivals structure for non-member be low --sia -- will will fall below 38 in the following weeks. up next, china's foreign exchange reserve falls below the $.5 trillion. pboc intervention. coming fresher -- coming pressure on the yuan. ♪ guy: 14 minutes past the hour. welcome back. you are watching the pulse pierced streaming on bloomberg.com. china

pharma is getting hit. any to merge to cut costs. we thought this may not happen before christmas.re, it looks like it is around the corner here it jonathan: offensive m&a does not sound optimistic. toon: we're getting industrial names having to combined -- having to combine and then split. bigpeople are facing challenges. they need to cut costs and they need to somehow get your and cut costs to survive. jonathan: to moscow we want to talk about -- two months ago we were going to talk about -- what does it mean for the other players? aaron: it is good to great the number one in the world. monsanto try to do a deal and they got rebuffed. you're going to have three big players shaking in their boots. the swiss are going to be asking themselves can they partner up. monsanto's going to be looking twond and seeing our biggest american competitors have just gotten bigger. what are we going to do? jonathan: is their way of looking at it like that? aaron: they wanted to do this was deal. them -- just locked just block to them over and over. they have to think about what they need to do and

we are seeing financials and pharma stocks driving that overall market lower today, falling to a two-weekin terms of movers, golden properties in hong kong surging as much as 65% before closing up a mere 54%. the company is selling off a stake in a tengion property to reinvest here in hong kong. on the other end, we are seeing shares of gemdale tanking today. we are seeing profit taking across that stock. we are counting down to the reopen in the shanghai markets at the top of this hour. emily: to say it has been a rough year for yahoo! may be the understatement of the year. from --ntments [indiscernible] 31%o! shares down year-to-date. then there's the executive exodus. .ackie rhesus what can the company offer investors in 2016? alik is still with us. you've been very vocal about this. very vocal. that is also an understatement. do you think yahoo! can be saved? om: they do not really have any relevance to the current user, internet users. the answer is no. 2016 will be very much like 2015, the growing irrelevance of the company. emily: allen, having invested in aol, how do you answer th